Palvella Therapeutics (PVLA) EBT (2013 - 2026)
Palvella Therapeutics (PVLA) reported EBT of -$15.8 million for Q1 2026, down 92.63% year-over-year from -$214.0 million in Q1 2025, and down 154.25% on a QoQ basis from $29.1 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of EBT data on file, last reported at -$15.8 million in Q1 2026.
- Quarterly EBT fell 92.63% year-over-year to -$15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.5 million (down 33.09% YoY) and the FY2025 annual result came in at $64000.0, changed N/A from the prior year.
- EBT slipped to -$15.8 million in Q1 2026 per PVLA's latest filing, from $29.1 million in the prior quarter.
- Across five years, EBT topped out at $29.1 million in Q4 2025 and bottomed at -$15.8 million in Q1 2026.
- The 5-year median for EBT is -$7.8 million (2022), against an average of -$3.6 million.
- The widest annual swing landed in 2023, when EBT surged 120.93%; it then sank 263.42% in 2024.
- Tracing PVLA's EBT over 5 years: stood at -$11.9 million in 2022, then jumped by 212.23% to $13.4 million in 2023, then rose by 0.72% to $13.5 million in 2024, then soared by 115.57% to $29.1 million in 2025, then slumped by 154.25% to -$15.8 million in 2026.
- Per Business Quant, the three latest PVLA EBT figures stand at -$15.8 million (Q1 2026), $29.1 million (Q4 2025), and -$11.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | 29.07 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | 13.48 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | -11.26 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | -15.15 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -12.20 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.01 Mn |
| Sep 30, 2021 | -19.01 Mn |
| Jun 30, 2021 | -16.76 Mn |
| Mar 31, 2021 | -5.06 Mn |
| Dec 31, 2020 | -12.40 Mn |
| Sep 30, 2020 | -12.94 Mn |
| Jun 30, 2020 | -4.53 Mn |
| Mar 31, 2020 | -3.54 Mn |
| Dec 31, 2019 | -771,000.00 |
| Sep 30, 2019 | -2.59 Mn |
| Jun 30, 2019 | -11.76 Mn |
| Mar 31, 2019 | -10.35 Mn |
| Dec 31, 2018 | -11.85 Mn |
| Sep 30, 2018 | -6.15 Mn |
| Jun 30, 2018 | -351,000.00 |
| Mar 31, 2018 | -8.71 Mn |
| Dec 31, 2017 | 7.64 Mn |
| Sep 30, 2017 | -6.91 Mn |
| Jun 30, 2017 | -9.27 Mn |
| Mar 31, 2017 | -7.99 Mn |
| Dec 31, 2016 | -6.40 Mn |
| Sep 30, 2016 | -6.20 Mn |
| Jun 30, 2016 | -5.88 Mn |
| Mar 31, 2016 | -4.16 Mn |
| Dec 31, 2015 | -2.74 Mn |
| Sep 30, 2015 | -3.88 Mn |
| Jun 30, 2015 | -3.53 Mn |
| Mar 31, 2015 | -3.70 Mn |
| Sep 30, 2014 | -2.02 Mn |
| Jun 30, 2014 | -2.88 Mn |
| Mar 31, 2014 | -779,923.00 |
| Dec 31, 2013 | -2,198.00 |
| Sep 30, 2013 | -5,762.00 |
| Jun 30, 2013 | -274.00 |